Chief Financial Officer
Glenn Miles has more than 30 years’ experience in a variety of accounting and finance roles. Prior to his appointment as Chief Financial Officer, Mr. Miles served the Company as a financial and accounting consultant since July 2018. Prior to joining the Company, Mr. Miles served as President and CFO of Catalytic Consulting LLC, a management advisory firm specializing in finance, accounting and operations, since 2015. From 2013 to 2015, Mr. Miles conducted research and engaged in thought leadership and panel discussions, focusing on finance in the healthcare and non-profit industries. From 2009 to 2013, Mr. Miles served as the Biopharma Controller for Developed Europe, Latin America and US Oncology at Pfizer. Prior to joining Pfizer, Mr. Miles served as Vice President – Global Expense Control and Analysis – Non-Personnel Expense at Lehman Brothers from 2006 to 2008. Prior to joining Lehman Brothers, Mr. Miles served in various finance and accounting roles with increasing responsibility at AT&T Mobility (formerly Cingular Wireless and BellSouth Mobility) from 1994 to 2006. Early in his career, Mr. Miles worked as an accountant at Grant Thornton (and a regional subscriber firm, Aldridge, Borden & Company, P.C.) from 1987 to 1994. Mr. Miles holds an MBA from Mercer University and a Bachelor of Science from the University of Alabama in Accounting. Mr. Miles is trained in Lean Six Sigma (Green Belt), is a CPA, and a member of FEI, AICPA, ACHE & HFMA.
President, Discovery and Early Development
Dr. Brandt is the co-founder of vivoPharm | A CGI Company. He is a biochemist and cell biologist with over 15 years experience in research programs of experimental oncology. Furthermore, he has immense experience in in vivo pharmacology and anti-cancer drug profiling. He received his Licence (BSc in Biochemistry and Animal Physiology) in 1986, and his PhD (in Biochemistry) in 1991 from the Martin-Luther University of Halle-Wittenberg, Germany. Dr. Brandt was employed at research positions at the National Cancer Institute in Bethesda, MD, USA and at Schering AG, Germany. Since 1990, Dr. Brandt has been active in the field of preclinical oncology. He led the Tumour Biology program at Novartis Pharma AG, Switzerland and established several transgenic mouse lines developing tumours under the control of oncogenes. During Dr. Brandt’s long career in the pharmaceutical industry he has acquired significant knowledge and expertise in leading business units and representation of services to the pre-clinical research market. Dr. Brandt is a member of the Scientific Advisory Board at Receptor Inc. in Toronto Canada and Propanc in Melbourne VIC, Australia.
PRESIDENT AND CHIEF EXECUTIVE OFFICER
John A. Roberts was appointed President and Chief Executive Officer of CGI in April 2018 following his role as Chief Operating Officer and Executive Vice President, Finance, a position he has held since he joined CGI in July 2016. Mr. Roberts brings deep operational and financial experience to CGI with a strong track record of disciplined growth, operational excellence and shareholder value creation in multiple public and private healthcare technology and service companies including InfoLogix, AdvantEdge Healthcare Solutions, Clarient and, most recently, VirMedica. His professional background includes a deep understanding of clinical and healthcare billing, diagnostics, clinical operations, and healthcare-focused IT. In addition Mr. Roberts is Chairman of the Board of Directors for the Drug Information Association (DIA), a global neutral forum enabling drug developers and regulators access to insights and collaboration.
Mr. Roberts has a Master of Business Administration and Bachelor of Science from the University of Maine. He has served as a recognized thought leader and expert panelist for numerous publications and programs related to corporate finance and mergers and acquisitions in the healthcare industry.
Chief Commercial Officer
Michael McCartney was appointed as Cancer Genetics, Inc.’s Chief Commercial Officer in June 2018. Mr. McCartney has more than 20 years of life sciences, diagnostic and lab services industry experience with senior level responsibilities in sales management, global marketing and business development. Prior to joining Cancer Genetics, Mr. McCartney served as the Chief Executive Officer at SciKon Innovation, Inc., an early-stage life science company, where he was responsible for guiding the company through fundraising activities as well as developing an exit strategy for the company. Prior to his appointment as CEO, Michael served as Chief Operating Officer at SciKon, where he was responsible for developing the sales and marketing organizations, creating the overall sales process, strategic direction, as well as company and individual goals. Early in his career, Mr. McCartney held positions across multiple disciplines at BioAgilytix Labs, Roche, Siemens and Abbott. Mr. McCartney holds a Master of Business Administration degree from LaSalle University in Philadelphia and a Bachelor’s degree in Business Administration with an emphasis on finance from Indiana University of Pennsylvania.
Executive Vice President, Precision Medicine and BioPharma Services
Bill Finger was appointed as Cancer Genetics, Inc.’s Executive Vice President, Precision Medicine and Pharma Services in January 2019. Mr. Finger has more than 25 years of laboratory services and diagnostics industry experience with a focus in Precision Medicine, Companion Diagnostics and Central Laboratory services. Prior to joining Cancer Genetics, Mr. Finger served as Managing Director of Precision Medicine and Diagnostics at Kineticos Life Sciences, a specialty consulting firm focused on developing growth oriented strategies and tactics to Life Sciences Companies. Prior to joining Kineticos in 2012, Mr. Finger served as the Global Director of Technical Services and Sales Operations at LabCorp Clinical Trials and was responsible for supporting internal customers (sales, operations, companion diagnostics and labs) and external customers (pharma, biotech, and CROs) with both technical and commercial strategies to help support clinical trials. While at LabCorp, Mr. Finger had oversight of Technical Services / Scientific Affairs to include technical lab support, pricing, sales operations, and LIMS globally across the LabCorp network of labs and also managed the preclinical lab, specimen management, and construction of the biorepository. Mr. Finger earned his Masters of Healthcare Administration from UNC-Chapel Hill and a BS in Medical Technology from the State University of New York at Plattsburgh.
Vice President, Biopharma Collaborations & Companion Diagnostics
Kamala K. Maddali, DVM, Ph.D, is Vice President, Biopharma Collaborations and Companion Diagnostics at Cancer Genetics Inc. She joined CGI in 2015, and plays a pivotal role in the biomarker and companion diagnostics strategy in the context of pharma novel drug development programs.
Dr. Maddali brings over 10 years of extensive experience of global P&L scientific and commercial management of clinical biomarker and companion diagnostics (CDx) services covering personalized medicine strategy. She has promoted the proper utilization of biomarkers, personalized medicine and diagnostics in drug development and patient management to bridge the gap between drug and diagnostic industries. She was Global Director Scientific Development -Biomarkers & Companion Diagnostics for Q2 Solutions (A Quintiles & Quest Diagnostics joint venture). She brings a lot of strategic values from her previous roles at Quest Diagnostics, Quintiles and Merck Schering Plough in the arena of biomarkers and companion diagnostics.
Dr. Maddali holds a DVM Ph.D., in Pharmacology from University of Missouri-Columbia and a DVM Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India.
Dr. Maddali is CGI’s Innovation Hero as recognized by Healthcare Heroes Finalist award by NJBIZ. She initiated an actively on-going “Biopharma Collaboration” campaign where she has implemented strategic initiatives to foster positive growth of the company through the provision of high-quality, innovative, responsive services. Her goal is to ensure that every patient’s voice is heard by helping patients and pharma partners implement the right test for the right patient, thus improving the global community health by innovating the right drug.
Vice President of Clinical Affairs and Site Operations
Dr. Ehab Elkhouly is a uniquely qualified professional in the healthcare industry with proven medical, business development and operational skills. Dr. Elkhouly’s specific areas of expertise include pathology, lab medicine and molecular diagnostics with an emphasis on Oncology. As a Research Scientist at the prestigious University of Southern California-Norris Comprehensive Cancer Center, he participated in colorectal and breast cancer studies, and also collaborated in grant budgeting. He was previously recruited by Response Genetics, Inc., and quickly promoted to Director of Operations. In this capacity, he coordinated business and scientific strategies, also instituting strong outreach and awareness programs to enhance marketing initiatives through effective advocacy and education. He met numerous challenges during his administrative training at USC-Keck Medical Center and Norris Comprehensive Cancer Center, improving fiscal protocols for clinical trials and enhancing overall operational effectiveness. Most recently, he coached a team through the 2015 Business Plan Competition at the University of California, Irvine, the Paul Merage School of Business. The team included faculty members, scientists and business leaders who developed a safe proprietary cell delivery system to improve blood glucose control and alleviate diabetes complications. The team was awarded First Place Prize and received considerable monetary rewards.
A third-generation M.D., Dr. Elkhouly graduated from Cairo University School of Medicine in his native Egypt, completed three years of pathology and lab medicine residency at the USC-Keck Hospital and LAC+USC Medical Center, later earned a Health Care MBA from UC, Irvine, the Paul Merage School of Business. He will soon receive his Six Sigma Lean Green Belt Program Certification. He is currently earning a Master of Science in Clinical, Biomedical and Translational Investigations from University of Southern California – Keck School of Medicine.
Dr. Singh-Kahlon brings more than 30 years of experience in clinical cytogenetics to CGI since joining in 2010. He has over 20 years of experience in Director positions, including the last seven years in cancer, at leading commercial cytogenetics laboratories, LabCorp and Genzyme, and earlier at the University of California School of Medicine in San Francisco. Dr. Singh-Kahlon is an active member of the American College of Medical Genetics (ACMG), American Society of Human Genetics (ASHG) and the Association of Molecular Pathology (AMP). Since being at CGI, Dr. Singh-Kahlon is focused on delivering high quality diagnostic reports while maintaining industry leading turnaround times. He is involved in the expansion of CGI’s FISH test menu by introducing new testing such as the cIg-FISH used in the diagnosis of multiple myeloma, and further FISH testing validation for molecular markers such as HER2 and in Gliomas used in clinical management of solid tumors.
Director, Molecular Diagnostics
Dr. Chen ncame to CGI in 2005. Her scientific focus has been on the identification and characterization of genomic alterations in B-cell lymphoma and their prognostic implications using modern molecular techniques, including microarrays. While at MSK, she was trained in the Molecular Diagnostic Laboratory at the New York Presbyterian Hospital and Memorial Sloan-Kettering Cancer Center. Dr. Chen is certified as a High-complexity Clinical Laboratory Director (HCLD) from American Board of Bioanalysis (ABB), and a certificate of qualification as a laboratory director from the New York State Department of Health. She is an active member of the Association of Molecular Pathology. At CGI, Dr. Chen supervised the establishment of the molecular diagnostic laboratory as well as validated and acquired licensure for clinical assays at CGI with New York State and Clinical Laboratory Improvement Amendment (CLIA). She oversaw the setting up of an automated system in CGI’s molecular diagnostic lab. Now she manages the operation of the molecular lab, reviews and reports test results, as well as directing the development and validation of new clinical tests.